Reversible Hair Loss in Lichen Planopilaris: Regrowth With Low-Dose Naltrexone and Platelet-Rich Plasma

June 2022 | Volume 21 | Issue 6 | 671 | Copyright © June 2022


Published online May 18, 2022

doi:10.36849/JDD.6810

Elizabeth J. Klein BAa*, Maria Karim BAb*, Randie Kim MDa, Kristen Lo Sicco MDa*, Jerry Shapiro MDa*

aRonald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, NY
bHackensack Meridian School of Medicine, Nutley, NJ

*Both authors contributed equally as co-first authors (Elizabeth J. Klein and Maria Karim) or as co-senior authors (Kristen Lo Sicco and Jerry Shapiro)

Abstract
Lichen planopilaris (LPP) is a cicatricial alopecia that presents with patchy or diffuse hair loss at the vertex or parietal scalp. The literature has limited evidence on treatments for this challenging disease, with most reports involving small groups of patients with varied or suboptimal clinical responses. Amongst individuals who do respond to therapy and eventually achieve disease remission, hair regrowth within scarred alopecic patches is rare.1 Herein, we report a patient with biopsy confirmed LPP who demonstrated remarkable hair regrowth at a previously scarred alopecic patch after initiating low-dose naltrexone (LDN) and platelet-rich plasma (PRP), despite minimal response to 4 months of prior therapy with intralesional corticosteroids, topical clobetasol, topical minoxidil, finasteride, doxycycline, and ketoconazole shampoo. This case highlights the importance of remaining flexible and diligent in therapeutic approaches to LPP and the need for more robust literature on prognosis and treatment options for LPP patients.

J Drugs Dermatol. 2022;21(6):671-673. doi:10.36849/JDD.6810

INTRODUCTION

Lichen planopilaris (LPP) is a cicatricial alopecia that presents with patchy or diffuse hair loss at the vertex or parietal scalp. Although there is no gold standard therapy, most interventions are immune modulating and aimed at reducing inflammation and terminating the scarring process to prevent further fibrosis.3 Even amongst patients who respond to therapy, hair loss at alopecic sites is generally considered permanent due to the condition's destruction of multipotent follicular stem cells.2,4 Here we present a case of reversible hair loss in a patient treated with topical, intralesional, and systemic therapy.

CASE REPORT

A 46-year-old Caucasian woman with a history of hypothyroidism, well controlled on Synthroid 100 mcg daily, presented to our clinic with significant hair shedding and scalp flaking occurring over the previous 10 months. She did not report any associated scalp pain, pruritus nor mucosal lesions.

On physical examination, the patient was found to have a small alopecic patch with surrounding scale at the central vertex of the scalp. Trichoscopy revealed perifollicular erythema and hyperkeratosis. A 4-mm punch biopsy was performed at the involved site. Histopathologic examination demonstrated follicular dropout characterized by fibrous tracts, diminished number of sebaceous glands, and polytrichia. Sparse lymphocytic inflammation with subtle interface changes within the zones of fibrosis was also noted (Figure 1). A pathologic diagnosis of lichen planopilaris (LPP) was made, confirming clinical suspicion.